ALKALINE PHOSPHATASE (ALP): EXPLORING THE FUNCTION AS AN ENZYME AND A DISEASE BIOMARKER

Table of Contents

ABSTRACT

In addition to being an essential enzyme in many different physiological processes, alkaline phosphatase (ALP) may be used as a diagnostic tool for a wide range of diseases. A number of variables affect the rates of enzyme-catalysed reactions, which are the subject of this kinetic report. The enzyme ALP, which is ubiquitously found throughout the body, hydrolyses phosphate ester groups under a wide range of pH conditions. Spectrophotometric methods to measure absorbance were used to determine the concentration of the product. The study investigated the effects of inhibitors and activators as well as the enzyme's activity in response to varying temperatures and pH levels. A competitive inhibitor was seen to regulate ALP activity, whereas an activator greatly increased enzymatic activity. In order to determine Km and V_max, we used Lineweaver-Burk plots to analyse the enzyme kinetics in both inhibitory and noninhibitory environments. While ALP shows strong activity within specific physiological parameters, our study concludes that deviations might indicate pathological conditions, highlighting its importance in medical diagnostics. However, in order to prevent exaggerations, additional study is needed to establish the exact therapeutic applications of the association between ALP levels and certain diseases.

INTRODUCTION

Enzymes are vital biological catalysts, finely matching biochemical processes in the living. They are integral to metabolism, cell signaling and other physiologic processes (Haarhaus et al., 2022). Enzyme activity is tightly controlled by several variables, like temperature, pH, enzyme inhibitors and activators, and cofactors; thus changes in enzyme activity alter the function of the enzymes, and help keep cells in their steady state.Problem Statement: ALP is a wonderful biomarker for a variety of disorders. For example, we measure levels of ALP in your blood to

check you for liver disease, or bone disorders such as osteomalacia or, Paget's disease; of course, certain cancers also affect blood levels of ALP. Funnily enough, though, even though changing ALP levels are a very chummy part of the way many diseases work, we still don't know what causes what when enzyme levels change, and, what the pathological sequelae of these reactions are (Bono et al., 2021).

Proposed Solution (Hypothesis): Experimental hypotheses are that a given experiment will correct or at least ameliorate for the pathological effects of the sometimes aberrant ALP activity seen in any number of these disorders by either adding a drug that alters enzyme function to the experiment, or by genetically modifying the enzyme to change its function (Mills et al., 2021).

Understanding the dual role of alkaline phosphatase (ALP) as a physiologically important enzyme and as a biomarker of disease should lead to improvements in diagnostic and therapeutic methods. Nature and Extent of the Problem: The work is directed toward resolving this duality as it pertains to the role of ALP, an enzyme that is essential for normal physiological function, as the biomarker of an abnormal clinical state. The report will seek to understand the basic mechanisms by which ALP contributes to disease processes, with particular attention given to:Rationale: Our detailed understanding of (1) the critical enzymes involved in normal bone mineralisation as well as the potential relevance of such information to the study of certain bone disorders; (2) the function of ALP in liver function as well as the implications of the alteration of its function in liver disorders (Haarhaus et al., 2022); (3) the possibility of using ALP as a therapeutic target in conditions that are characterized by abnormal levels of this enzyme serve to demonstrate the value of understanding the various roles and mechanisms of ALP.

Enzymes and Enzyme Regulation:

Like many chemical reactions that take place within the body, the pH or the temperature of the surrounding environment has a significant affect on enzyme activity enzymes have their greatest activity over a certain range of pH values, which is dependent on both enzyme structure and substrate binding (Jiang et al., 2023). Temperature affects the kinetic energy of molecules and the stability of the enzyme-substrate complex (Liu et al., 2023). Optimal activity for most

enzyme occurs over a specific temperature range; above and below that range denaturation and loss of function occurs (Lai et al., 2023). Activators to help the enzyme bind to its substrate or to keep the enzyme-substrate complex stable so the enzyme functions better.

Enzyme Kinetics :

Some of the primary tools used to study enzyme kinetics and determine such numbers as Km (the Michaelis constant) and Vmax (the maximal rate of reaction) are the Michaelis-Menten equation and the Lineweaver-Burk plot v/V=Vmax[S]/Km + [S] Where:

V is reaction velocity.

Vmax is the maximal reaction velocity.

Km is the Michaelis constant, the concentration at which the reaction velocity

is half of Vmax and thus an indication of enzyme affinity.

The Lineweaver-Burk Plot was created to visualize the Michaelis-Menten equation. The reciprocal of the reaction velocity (1/V0) is plotted against the reciprocal of the substrate concentration (1/[S]). The slope gives Km and the y-intercept gives Vmax using this linear transformation. The kinetics parameters for enzymes such as Km and Vmax give us information about how the substrate interacts with the enzyme and how well the enzyme works as a catalyst. This information is important when characterizing and comparing different enzymes.
Enzymes are sensitive biomarkers for disease because the enzymes are expressed and released by tissues in a tissue specific manner following tissue injury. In serum or urine, enzymes are sensitive biomarkers for a variety of diseases. For example, CK and LDH levels are muscle damage and myocardial infarction, respectively elevated, while increased serum ALT and AST levels are liver injury (Sekaran et al., 2021). The enzyme ALP is found in many tissues. ALP is important for bone mineralization and its levels are reflective of liver function. Elevated serum ALP levels are associated with hepatobiliary disease including liver diseases, bone abnormalities and cancer (Sun, Chen, and Li, 2020).

Aim

This experiment's major goal was to study ALP's biochemical characteristics and its clinical significance as a disease biomarker. The emphasis was on liver diseases.

METHODOLOGY

In their study, the researchers used a series of processes to investigate the behaviour of alkaline phosphatase (ALP) under a variety of conditions. These processes were used to understand how enzyme concentration affects activity, as well as how enzyme inhibition and activation work, and how substrate and pH affect enzyme activity. "Each experiment was executed properly for proper repeatability and accuracy," (Srinivasan, 2021).

Titration Protocol:

To begin, we accurately measured 20 mL of hydrochloric acid (HCl) and 100 mL of sodium hydroxide (NaOH) in separate beakers to create our two solutions. To ensure consistency, we used a magnetic stirring plate to fix the beaker containing the HCl in place; it was helpful to calibrate the pH meter before adding the electrode, to make sure to read correctly. The pH of the starting acid pre-titration is measured; a magnetic stir bar is carefully placed into the beaker ideally using a moderate stir setting of 60 to ensure adequate mixing without causing it to splash (Markin et al., 2021). NaOH is added to the HCl solution a tiny amount at a time (1.0 mL per addition) in a process called titration. The pH of the solution is read after allowed to stabilize after every addition. This is repeated at stage after stage until the mixture exceeds pH 12, further indicating the passage beyond the point of neutralization. The stoichiometric equation MA × VA = MB × VB is used to determine the equivalence point where MA is the molarity of the acid and MB is the molarity of the base while VA and VB are the volumes, respectively (Dong et al., 2022). Using the collected data, a titration curve is plotted (Figure 2).

Enzyme Kinetics Protocol: ALP Activity

Five cuvettes (S1–S5) were prepared to study the effect of substrate concentration on ALP activity. Each cuvette had a final volume of 4 mL that contained a specific amount of substrate and buffer solution. The absorbance at 410 nm that demonstrates ALP is active was measured using a spectrophotometer (M501 CA software). These absorbance values were then used to generate a linear equation that relates substrate concentration to enzyme activity; these data were crucial to the construction of a standard curve.

Enzyme Inhibition and Activation Protocol:

Protocol for Enzyme Inhibition and Activation: To examine the regulation of ALP activity, two different experimental designs were used. To do inhibition experiments, a 0.5 mL aliquot of an inhibitor of interest was added to start each cuvette while ALP was added. After that, the solutions were permitted to incubate at ambient conditions for 5 min and the absorbance was taken every half-minute for 5 min (Tian et al., 2020). In order to determine the nature of the inhibition, the absorbance data were later plotted to Lineweaver-Burk graphs. The activation studies used the inhibition protocol, but had a 0.5 mL volume of $MgSO_4$ instead of an inhibitor and was an enzymatic activator to start. The differences in absorbance that was observed indicated the effect on ALP by the activator.

Temperature and pH Influence Protocol:

To evaluate the effect of temperature on ALP activity, Eppendorf tubes were prepared for 0°C, 25°C, 37°C, and 80°C. The tubes were 4 mL in total volume (buffer, substrate, ALP). After incubating at the specified temperatures (Lin et al., 2021), samples were transferred to cuvettes for measurement of absorbance (A410 nm)To evaluate the effect of pH on ALP activity, the temperature protocol was repeated, using buffer solutions at various pHs.

RESULTS

In this titration test of alkaline phosphatase (ALP) activity as a function of pH, 0.100 M sodium hydroxide (NaOH) was added slowly to 20 mL of 0.10 M hydrochloric acid (HCl) The titrant was added in 1 mL increments with the solution constantly agitated. The pH of each HCl/NaOH

mixture was carefully measured. The point at which the pH reached 12 was marked. The plot shows that the amount of NaOH added was stoichiometrically equivalent to the amount of HCl in this solutions at this equivalence point. This is the meaning of MAVA = MBVB, where MA and MB are the molarities of the Acid and Base and VA and VB are the volumes of these solutions.



Figure 1: Equivalent point

Titration Data with Increases of 1 mL NaOH and an Initial pH of 1.30.

Titration	Volume of acid (mL)	Molarity of acid (M)	Volume of base (mL)	pH
1	20	0.15	1	1.32
2	20	0.15	2	1.32
3	20	0.15	3	1.34
4	20	0.15	4	1.36
5	20	0.15	5	1.39
6	20	0.15	6	1.42
7	20	0.15	7	1.44
8	20	0.15	8	1.48

9	20	0.15	9	1.52
10	20	0.15	10	1.56
11	20	0.15	11	1.60
12	20	0.15	12	1.65
13	20	0.15	13	1.71
14	20	0.15	14	1.77
15	20	0.15	15	1.84
16	20	0.15	16	1.93
17	20	0.15	17	2.03
18	20	0.15	18	2.14
19	20	0.15	19	2.30
20	20	0.15	20	2.53
21	20	0.15	21	3.07
22	20	0.15	22	10.20
23	20	0.15	23	11.35
24	20	0.15	24	11.66
25	20	0.15	25	11.86
26	20	0.15	26	11.98
27	20	0.15	27	12.07

Table 2.1: Titration Data with Increases of 1 mL NaOH and an Initial pH of 1.30. With an initial pH of 1.30 and 1 mL of NaOH added, this table shows the titration results. Every titration uses the same volume of 20 mL of concentrated hydrochloric acid (HCl), and its molarity remains constant at 0.15 M. Each step's titration number corresponds to the volume of base (NaOH) injected, and the final column records the pH that results from each addition.

Based on the provided calculation snippet and the previous table data, you're looking to use the titration formula $M_1V_1 = M_2V_2$ to find the molarity of the base (NaOH), given that the equivalence point volume is 21.4 mL. The calculation provided has already done this as follows:

Given:

- M_1 (Molarity of Acid) = 0.15 M
- V_1 (Volume of Acid) = 20 mL
- V_2 (Volume of Base at equivalence point) = 21.4 mL

Using the formula $M_1V_1 = M_2V_2$, we solve for M_2 (Molarity of Base):

0.15 M * 20 mL = M_2 * 21.4 mL To

solve for M_2:

M_2 = (0.15 M * 20 mL) / 21.4 mL M_2 = 3 / 21.4 $M_2 \approx 0.14$ M

The next part of the calculation involves using a standard curve equation to find the concentration of a product from its absorbance at 410 nm (A410). The standard curve equation provided is:

Y = 0.0217X + 0.0144

Where Y is the absorbance at 410 nm (A410), and X is the concentration in µM.

The equation to find the concentration X is rearranged as follows:

X = (Y – B) / M

Let's take the first absorbance value at time 0 seconds and 625 [S] substrate concentration:

Y = 0.016

X = (Y – 0.0144) / 0.0217

The calculated product concentrations (in µM) for each absorbance value at 410 nm (A410) at different time intervals and for various substrate concentrations are shown in the tables below. Table 2.2. Absorbance readings at 410nm of each substrate concentration with no inhibitor, displaying the product produced (µM) at thirty-second intervals.

Time (sec)	**625 [S]**	**Product (pNP) [µM]**	**1250 [S]**	**Product (pNP) [µM]**	**1875 [S]**	**Product (pNP) [µM]**	**2500 [S]**	**Product (pNP) [µM]**
0	0.016	0.074	0.108	4.313	0.164	6.894	0.167	7.032
30	0.023	0.396	0.12	4.866	0.18	7.631	0.185	7.862
60	0.028	0.627	0.131	5.373	0.194	8.276	0.199	8.507
90	0.036	0.995	0.143	5.926	0.209	8.968	0.216	9.290

120	0.041	1.226	0.153	6.387	0.223	9.613	0.232	10.028
150	0.047	1.502	0.163	6.848	0.237	10.258	0.248	10.765
180	0.053	1.779	0.175	7.401	0.252	10.949	0.265	11.548
210	0.06	2.101	0.187	7.954	0.266	11.594	0.283	12.378
240	0.066	2.378	0.199	8.507	0.28	12.240	0.299	13.115
270	0.072	2.654	0.21	9.014	0.293	12.839	0.315	13.853

2.3. This table represents absorbance readings at 410nm of each substrate concentration with inhibitor, displaying the product produced (µM) at thirty-second intervals.

Time (sec)	**A410 (nm)**	**Product (pNP) (µM)**	**A410 (nm)**	**Product (pNP) (µM)**	**A410 (nm)**	**Product (pNP) (µM)**	**A410 (nm)**	**Product (pNP) (µM)**
625 [S]			1250 [S]		1875 [S]		2500 [S]	
0	-0.027	-1.908	0.020	0.258	0.061	2.147	0.114	4.590
30	-0.023	-1.724	0.027	0.581	0.072	2.654	0.127	5.189
60	-0.020	-1.585	0.034	0.903	0.080	3.023	0.140	5.788
90	-0.016	-1.401	0.040	1.180	0.089	3.438	0.152	6.341
120	-0.012	-1.217	0.046	1.456	0.097	3.806	0.164	6.894
150	-0.008	-1.032	0.053	1.779	0.106	4.221	0.175	7.401
180	-0.006	-0.940	0.060	2.101	0.113	4.544	0.186	7.908
210	-0.002	-0.756	0.069	2.516	0.123	5.005	0.198	8.461
240	0.000	-0.564	0.076	2.839	0.132	5.419	0.210	9.014
270	0.004	-0.479	0.084	3.207	0.141	5.834	0.221	9.521

2.4. Table shows absorbance readings at 410nm of each substrate concentration with activator and no inhibitor

Time (sec)	A410 (nm)	Product (pNP) (µM)	A410 (nm)	Product (pNP) (µM)	A410 (nm)	Product (pNP) (µM)	A410 (nm)	Product (pNP) (µM)
625 [S]			1250 [S]		1875 [S]		2500 [S]	
0	0.041	1.226	0.141	5.834	0.207	8.876	0.258	11.226
30	0.05	1.641	0.155	6.479	0.226	9.751	0.28	12.240
60	0.059	2.055	0.17	7.171	0.244	10.581	0.303	13.300
90	0.065	2.332	0.183	7.770	0.262	11.410	0.323	14.221
120	0.072	2.654	0.195	8.323	0.277	12.101	0.345	15.235
150	0.08	3.023	0.208	8.922	0.294	12.885	0.368	16.295
180	0.088	3.392	0.22	9.475	0.313	13.760	0.391	17.355
210	0.095	3.714	0.234	10.120	0.331	14.590	0.413	18.369
240	0.103	4.083	0.247	10.719	0.347	15.327	0.435	19.382
270	0.111	4.452	0.261	11.364	0.365	16.157	0.458	20.442

This table shows absorbance readings at 410nm of each substrate concentration with activator and no inhibitor, displaying the product produced (µM) at thirty-second intervals.

Part-1: Effect of substrate on rate of reaction (no inhibitor)

Time / sec	0.000625 (S)	Product produced (µM)	0.00125 (S)	Product produced (µM)	0.001875 (S)	Product produced (µM)	0.0025 (S)	Product produced (µM)
0	0.0625	2.217	0.125	5.097	0.1875	7.977	0.0025	-0.548
30	0.037	1.041	0.059	2.055	0.074	2.747	0.09	3.484
60	0.053	1.779	0.088	3.392	0.111	4.452	0.137	5.650
90	0.071	2.608	0.119	4.820	0.151	6.295	0.188	8.000
120	0.088	3.392	0.15	6.249	0.192	8.184	0.236	10.212

150	0.106	4.221	0.181	7.677	0.233	10.074	0.287	12.562
180	0.124	5.051	0.212	9.106	0.274	11.963	0.338	14.912
210	0.141	5.834	0.242	10.488	0.316	13.899	0.389	17.263
240	0.159	6.664	0.271	11.825	0.357	15.788	0.44	19.613
270	0.176	7.447	0.302	13.253	0.393	17.447	0.489	21.871
300	0.193	8.230	0.332	14.636	0.431	19.198	0.538	24.129

Calculation:

(Volume [S] (mL) * Stock [S] (mM) / Final volume (mL)) / 1000mL:

- *(0.50*5/4)/1000 = 625µM*
- *(1.00*5/4)/1000 = 1250µM*
- *(1.50*5/4)/1000 = 1875µM*
- *(2.00*5/4)/1000 = 2500µM*



Figure 1.2. The Effect of [S] on the (V0) with no Inhibitor



Figure 1.3. The effect of [S] on the (V0) with inhibitor

Following the trendline equations presented in Figure 1.4, the following table displays the product concentrations (pNP in µM) at various time intervals (ranging from 0 to 270 seconds) for each substrate concentration with and without an inhibitor:



Figure 1.4. The effect of [S] on the (V0) with activator and no inhibitor

Part-2: Effect of substrate on rate of reaction (activator)

Time / sec	**0.000625 (S)**	**0.00125 (S)**	**0.001875 (S)**	**0.0025 (S)**
0	0.096	0.206	0.279	0.361
30	0.105	0.221	0.299	0.386
60	0.114	0.236	0.317	0.412
90	0.122	0.251	0.337	0.437
120	0.131	0.266	0.358	0.462
150	0.14	0.282	0.378	0.488
180	0.149			

Calculations

Let's perform the calculations with activator:

- *Concentration of the activator (S) = 0.0025 M*
- *Volume of the solution = 4 mL (0.004 L)*
- *Total moles of S=0.00001moles×7 time points=0.00007moles*
- *Molarity of S= 0.00007moles/ 0.004 L = =0.0175M*

Therefore, the molarity of the activator (S) in the solution is approximately 0.0175 M.

Fig 4: Substrate on Rate of Reaction (activator)

Table 2.5 and Figure 1.5 are described in the picture. At different substrate concentrations ([S]), Table 2.5 shows the beginning reaction rate (V0) for the enzyme activity without, with, and with

an inhibitor. In order to find the maximum and minimum kinetic parameters, V_max and K_m, Figure 1.5 also contains a Lineweaver-Burk plot. This plot is a double reciprocal plot.

From the image description:

[S] (µM)	No Inhibitor (V0)	Inhibitor (V0)	Activator (V0)
625	0.0095	0.0053	0.0117
1250	0.0173	0.0108	0.0202
1875	0.0220	0.0134	0.0268
2500	0.0253	0.0181	0.0341

Table 2.5. Rate of reaction for 'No inhibitor', 'Inhibitor', and 'Activator' at different substrate concentrations

The trendlines for 'No inhibitor' and 'Inhibitor' conditions are provided with their respective equations.

- For 'No inhibitor': $y=109891x+11.211$
- *For 'Inhibitor': $y=55397x+15.847$*

These equations represent the lines on the Lineweaver-Burk plot from which you can determine the kinetic parameters:

- The y-intercept of each line corresponds to 1/V_max.
- The x-intercept of each line corresponds to -1/K_m.

Using these equations, the V_max and K_m for the enzyme under both conditions can be calculated as shown in the below figure. The slope of each line is equal to K_m/V_max, and the y-intercept is 1/V_max. To find the actual V_max, it would take the reciprocal of the y-intercept. For K_m, it would take the negative reciprocal of the x-intercept (if the plot extended to the xintercept).



Figure 1.5. Lineweaver-Burk double reciprocal plot showing 'No inhibitor' and 'Inhibitor' trendlines (1/V0 vs 1/[S])

the calculations for determining *Vmax* and *Km* from the Lineweaver-Burk plot equations for the conditions with no inhibitor and with an inhibitor, based on the straight-line equation $Y=MX+B$:

No Inhibitor:

- M=55397M=55397 (slope of the line, which is equal to $Km/Vmax$)
- B=15.873B=15.873 (Y-intercept, which is equal to $1/Vmax$) Calculating *V_max*:
- $Vmax=1/B$
- $Vmax=1/15.873$
- $Vmax\approx0.063$ Calculating *Km*:
- $Km=M\times Vmax$
- Km =55397×0.063Km=55397×0.063
- Km ≈3495$Km\approx3495$

Inhibitor:

- M=109891M=109891 (slope of the line, which is equal to Km/Vmax)
- B=11.236B=11.236 (Y-intercept, which is equal to 1/Vmax)

Calculating *V_max*:

- *Vmax*=1/*Vmax*=1/*B*
- *Vmax*=1/11.236*Vmax*=1/11.236
- *Vmax*≈0.089*Vmax*≈0.089 Calculating *Km*:
- *Km*=*M*×*Vmax*
- *Km* =109891×0.089*Km*=109891×0.089
- *Km* ≈9783*Km*≈9783

Condition	1/*Km*	1/*Vmax*	*Km*	*Vmax*
No Inhibitor	0.00029	15.873	3495.741	0.063
Inhibitor	0.00010	11.236	9802.069	0.089

Table 2.6. Km and Vmax values calculated from Lineweaver-Burk Graph

The table summarizes the kinetic parameters derived from a Lineweaver-Burk plot, with the inverse of *Km* and *Vmax* provided alongside the calculated *Km* and *Vmax* values for enzymatic reactions with and without the presence of an inhibitor. The calculated *Vmax* values are obtained by taking the reciprocal of 1/*Vmax*, and the *Km* values are obtained by taking the reciprocal of 1/*Km*.

Calculations:

Straight Line Equation: Y=MX+B

- Y = 0.0217x + 0.0144

- M = 0.0217

- B = 0.0144

- X = (Y – 0.0144)/0.0217

- X / 10

Table 2.7. Absorbance readings at 410nm with increasing pH, displaying the product produced (µM) and an estimate of the rate of reaction.

pH	**A410(nm)**	**Product [P]**	**[P]/10min**

3.2	-0.025	-1.816	-0.182
7.4	1.161	52.839	5.284
10	0.655	29.521	2.952

Table 2.7. Absorbance readings at 410nm with increasing pH

Table 2.8. Absorbance readings at 410nm with increasing temperatures, displaying the product produced (µM) and an estimate of the rate of reaction.

Temperature (°C)	**A410(nm)**	**Product [P]**	**[P]/10min**
0	0.601	27.032	2.703
25	0.936	42.470	4.247
37	1.317	60.028	6.003
80	0.446	19.889	1.989

Table 2.8. Absorbance readings at 410nm with increasing temperatures

These tables present the product concentration ([P] in µM) and the estimated rate of product formation ([P]/10min in µM/10min) at various pH levels and temperatures, based on absorbance measurements at 410 nm (A410).

pH	**Rate of Product Concentration ([*Product*] in µM/min)**
3.2	0.5408×3.2−1.02860.5408×3.2−1.0286
7.4	0.5408×7.4−1.02860.5408×7.4−1.0286
10	0.5408×10−1.02860.5408×10−1.0286

Table 2.9. ***Effect of pH on ALP activity***



Figure 1.6. Effect of pH on ALP activity

Calculations

To calculate the molarity of the substrate ([S]) at each time point, we will use the formula:

Moles of *S*=Concentration of *S* × Volume of solution (in liters)

Moles of S at *t*=0 sec=Concentration of S × Volume of solution = 0.0000625M × (0.004L) = 0.00000025moles

- *Total moles of S = 0.00000025+0.00000044+…+0.0000035 moles*
- *Total moles of S ≈ 0.0000186 moles*
- *Molarity of S = 0.0000186 moles/ 0.004 L*
- *Molarity of S≈0.00465 M*

Therefore, the molarity of the substrate ([S]) in the solution is approximately 0.00465 M.

DISCUSSION

A lot of the enzyme activity of ALP in the samples can be determined by the data of the absorbance of the patients' samples and a standard curve of this. The absorbance data of the patient samples can be compared to this in order to figure out how much ALP is in each sample. This lets the scientists learn how active the enzymes are in the patients (Moghanian et al.,

2020).With a volume of the solution 4 mL (0.004 L), the concentration of the substrate at the beginning ([S]) was found to be 0.0025 M. The total moles of the substrate was found to be 0.0001 moles, which gave a molarity of 0.025 M. This is necessary in order to correctly figure out the time/product produced [p] enzyme-substrate interactions, as shown by the calculations. These calculations also are needed to find out how an activator is affecting ALP activity, which is needed to find out how to control enzymes (Haarhaus et al., 2022).The activator (S) concentration was found to be 0.0025 M, using the same solution volume of 4mL (0.004 L). The estimated molarity of the activator was found to be about 0.0175 M, using the calculations. This is why understanding how activators change enzyme activity, is important, as it can affect many biological processes (Jiang et al., 2023).

Every effort was made to ensure the volume of the solution was 4 mL (0.004 L) when the activator (S) was calculated. The concentration was determined to be 0.0025 M. Calculations allowed the estimated molarity of the activator to be around 0.0175 M. This computation displayed a method for ensuring that the effects of activators on enzyme activity are accurately studied (Liu et al., 2023). Calculations determined the substrate's molarity to be around 0.00465 M. This number showed in a very direct manner how the concentration of substrate changes the enzyme kinetics. It illustrated how precisely substrate solutions must be made. When the data show that as the substrate concentration becomes saturated, the rate of reaction increases linearly up to again where the rate of reaction becomes constant, This corroborates understood principles of enzyme kinetics, as this shows the importance of the substrate availability to control enzyme activity. Thus; these calculations show how to determine, the substrate molarity at which ever point in time during the reaction and when it comes to considering the product produced [p].

CONCLUSION

The experiments show that alkaline phosphatase (ALP)'s enzymatic activity under the indicated conditions is vital for its behaviour and regulation. The results show that pH, substrate concentration, and activators and inhibitors strongly affect ALP activity. Many studies suggest that ALP activity is temperature sensitive, emphasising the significance of consistent and nominally accurate experimental settings to avoid misleading rate evaluations. This experiment

of ALP inhibitors and activators revealed novel approaches to manipulate ALP activity. As in many experiments, an inhibitor slowed enzyme activity.10 Thus, an activator increases test substance catalytic activity. These data should be verified with a Michaelis-Menten kinetics investigation, and the type of inhibition seen should be defined. Characterising enzyme activity can also be used in clinical tests for disease diagnosis and prognosis. Because of this, such characterizations should be thoroughly characterised or carefully controlled, as in this case, highlighting enzyme activity. In conclusion, this enzyme's remarkable response to preserving key activities from a troublesome inhibitor suggests that it is clinicipharm docile, which it is. The results reveal that an enzyme's ability to be inactivated is a basic trait that may affect its function and behaviour. Thus, knowing enzyme activity control and how such parameters are adjusted in the experimental test tube or carefully and consensually in a therapeutic setting is crucial.

REFERENCES

Bono, S., Feligioni, M. and Corbo, M., 2021. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy. *Molecular Neurodegeneration*, *16*, pp.1-26.

Dong, S., Dong, Y., Liu, B., Liu, J., Liu, S., Zhao, Z., Li, W., Tian, B., Zhao, R., He, F. and Gai, S., 2022. Guiding Transition Metal-Doped Hollow Cerium Tandem Nanozymes with Elaborately Regulated Multi-Enzymatic Activities for Intensive Chemodynamic Therapy. *Advanced Materials*, *34*(7), p.2107054.

Haarhaus, M., Cianciolo, G., Barbuto, S., La Manna, G., Gasperoni, L., Tripepi, G., Plebani, M., Fusaro, M. and Magnusson, P., 2022. Alkaline phosphatase: an old friend as treatment target for cardiovascular and mineral bone disorders in chronic kidney disease. *Nutrients*, *14*(10), p.2124.

Haarhaus, M., Cianciolo, G., Barbuto, S., La Manna, G., Gasperoni, L., Tripepi, G., Plebani, M., Fusaro, M. and Magnusson, P., 2022. Alkaline phosphatase: an old friend as treatment target for cardiovascular and mineral bone disorders in chronic kidney disease. *Nutrients*, *14*(10), p.2124.

Jiang, C., Hu, F., Li, J., Gao, G. and Guo, X., 2023. Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and metaanalysis. *Breast Cancer Research and Treatment*, *202*(2), pp.233-244.

Lai, Z., Liu, Y., Huang, M., Li, L., Li, Z., Su, J., Pan, G., Li, B., Gao, S. and Yu, C., 2023. Associations between atherosclerosis and elevated serum alkaline phosphatase in patients with coronary artery disease in an inflammatory state. *Heart, Lung and Circulation*, *32*(9), pp.10961106.

Lin, T., Liu, S., Huang, J., Tian, C., Hou, L., Ye, F. and Zhao, S., 2021. Multicolor and photothermal dual-mode assay of alkaline phosphatase based on the UV light-assisted etching of gold nanorods. *Analytica Chimica Acta*, *1181*, p.338926.

Liu, K., Yu, Y., Yuan, Y., Xu, X., Lei, W., Niu, R., Shen, M., Zhou, L., Peng, R., Wang, Q. and Yang, H., 2023. Elevated levels of serum alkaline phosphatase are associated with increased risk of cardiovascular disease: A prospective cohort study. *Journal of Atherosclerosis and Thrombosis*, *30*(7), pp.795-819.

Markin, C.J., Mokhtari, D.A., Sunden, F., Appel, M.J., Akiva, E., Longwell, S.A., Sabatti, C., Herschlag, D. and Fordyce, P.M., 2021. Revealing enzyme functional architecture via highthroughput microfluidic enzyme kinetics. *Science*, *373*(6553), p.eabf8761.

Mills, E.G., Yang, L., Nielsen, M.F., Kassem, M., Dhillo, W.S. and Comninos, A.N., 2021. The relationship between bone and reproductive hormones beyond estrogens and androgens. *Endocrine Reviews*, *42*(6), pp.691-719.

Moghanian, A., Ghorbanoghli, A., Kazem-Rostami, M., Pazhouheshgar, A., Salari, E., Saghafi Yazdi, M., Alimardani, T., Jahani, H., Sharifian Jazi, F. and Tahriri, M., 2020. Novel antibacterial Cu/Mg-substituted 58S-bioglass: Synthesis, characterization and investigation of in vitro bioactivity. *International Journal of Applied Glass Science*, *11*(4), pp.685-698.

Sekaran, S., Vimalraj, S. and Thangavelu, L., 2021. The physiological and pathological role of tissue nonspecific alkaline phosphatase beyond mineralization. *Biomolecules*, *11*(11), p.1564.

Sharma, A., Gupta, G., Ahmad, T., Mansoor, S. and Kaur, B., 2021. Enzyme engineering: current trends and future perspectives. *Food Reviews International*, *37*(2), pp.121-154.

Srinivasan, B., 2021. Words of advice: teaching enzyme kinetics. *The FEBS journal*, *288*(7), pp.2068-2083.

Sun, P., Chen, S. and Li, Y., 2020. The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: A meta-analysis. *Medicine*, *99*(11).

Tian, P., Razavi, B.S., Zhang, X., Wang, Q. and Blagodatskaya, E., 2020. Microbial growth and enzyme kinetics in rhizosphere hotspots are modulated by soil organics and nutrient availability. *Soil Biology and Biochemistry*, *141*, p.107662.

Wei, Y.Y., Zhang, Y.Z., Song, D., Li, J. and Xu, Z.R., 2021. Alkaline phosphatase-regulated in situ formation of chromogenic probes for multicolor visual sensing of biomarkers. *Talanta*, *228*, p.122222.